^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AMT-562

    i
    Other names: AMT-562
    Company:
    Multitude Therap
    Drug class:
    Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate
    Related drugs:
    4ms
    AMT-562 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=72, Recruiting, Multitude Therapeutics (Australia) Pty Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    AMT-562
    10ms
    AMT-562 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Multitude Therapeutics (Australia) Pty Ltd
    New P1 trial • Metastases
    |
    AMT-562
    1year
    AMT-562, a novel HER3-targeting antibody drug conjugate, demonstrates a potential to broaden therapeutic opportunities for HER3-expressing tumors. (PubMed, Mol Cancer Ther)
    Pharmacokinetics and safety profiles of AMT-562 were favorable and the highest dose lacking severe toxicity was 30 mg/kg in cynomolgus monkeys. AMT-562 has potential to be a superior HER3-targeting ADC with a higher therapeutic window that can overcome resistance to generate higher percentage and more durable responses in U3-1402-insensitive tumors.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    ERBB3 expression
    |
    patritumab deruxtecan (U3-1402) • AMT-562